Cargando…

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination

HPV-023 (NCT00518336; ClinicalTrial.gov) is a long-term follow-up of an initial double-blind, randomized (1:1), placebo-controlled study (HPV-001, NCT00689741) evaluating the efficacy against human papillomavirus (HPV)-16/18 infection and associated cyto-histopathological abnormalities, persistence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naud, Paulo S, Roteli-Martins, Cecilia M, De Carvalho, Newton S, Teixeira, Julio C, de Borba, Paola C, Sanchez, Nervo, Zahaf, Toufik, Catteau, Gregory, Geeraerts, Brecht, Descamps, Dominique
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896780/ https://www.ncbi.nlm.nih.gov/pubmed/25424918 http://dx.doi.org/10.4161/hv.29532

Ejemplares similares

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults
por: Lal, Himal, et al.
Publicado: (2013)

Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial
por: Ramanakumar, Agnihotram V, et al.
Publicado: (2016)

HPV Vaccines: Separating Myths from Reality
por: Teixeira, Julio César, et al.
Publicado: (2019)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

HPV Vaccination and Screening with High-Performance Test: Brazilian Evidence
por: Teixeira, Julio Cesar, et al.
Publicado: (2021)

Assurance in vaccine efficacy clinical trial design based on immunological responses
por: Callegaro, Andrea, et al.
Publicado: (2021)

CPS94-RF #6 Réunion du 11/04/94
por: Arruat, Μ, et al.
Publicado: (1994)

CPS94-RF #7 Réunion du 19/04/94
por: Garoby, R
Publicado: (1994)

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
por: Pinto, Ligia A., et al.
Publicado: (2018)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014)

The use of urine in the follow-up of HPV vaccine trials
por: Vorsters, Alex, et al.
Publicado: (2015)

Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine
por: Callegaro, Andrea, et al.
Publicado: (2021)

A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
por: Schwarz, Tino F., et al.
Publicado: (2019)

Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16/18 AS04-adjuvanted vaccine: where is the greatest benefit for cervical cancer prevention in Italy?
por: Bonanni, Paolo, et al.
Publicado: (2015)

Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: Results from a randomized controlled trial
por: Zhu, Feng-Cai, et al.
Publicado: (2014)

Minutes of the IPP Meeting held on 13 04 94
por: Cowan, G
Publicado: (1994)

Intentions for catch-up HPV vaccination in Japan: an internet survey
por: Nakagawa, Satoshi, et al.
Publicado: (2023)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Postpartum HPV Vaccination Rate and Differences in Background Characteristics Between HPV Vaccinated and Unvaccinated Postpartum Women: Strict Monitoring and Follow-Up of Postpartum HPV Vaccination Program
por: Lee, Chung-Yuan, et al.
Publicado: (2021)

Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study
por: Schwarz, T, et al.
Publicado: (2015)

Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women: Open follow-up of a randomized clinical trial up to 4 years post-vaccination
por: Konno, Ryo, et al.
Publicado: (2014)

Minutes of the Lifetime / Mixing Meeting held on 28 04 94
por: Moser, H G
Publicado: (1994)

Minutes of the Lifetime / Mixing Meeting held on 04-07-94
por: Moser, H G
Publicado: (1994)

Minutes of the Charm Meeting held at CERN on 04 03 94
por: Maggi, M
Publicado: (1994)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Is the catch‐up program of HPV vaccination for Japanese adult women effective or not?
por: Kurokawa, Tetsuji
Publicado: (2020)

Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017)

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: Results from a randomized study
por: Romanowski, Barbara, et al.
Publicado: (2014)

Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine
por: Gupta, Gaurav, et al.
Publicado: (2016)

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge
por: Hoes, J., et al.
Publicado: (2021)

Easy access to vaccination was important for adherence during the 2016–2019 HPV catch-up vaccination in Norway
por: van Boetzelaer, E., et al.
Publicado: (2021)

Can Catch-Up Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV Vaccine in Japan?
por: Yagi, Asami, et al.
Publicado: (2022)

Electroweak Heavy Flavour Physics Minutes held on 21 04 94
por: Carr, J
Publicado: (1994)

Disparities among Japanese municipalities in recommendations for routine and catch‐up HPV vaccinations
por: Watanabe, Yuko, et al.
Publicado: (2023)

The one-dose schedule opens the door to rapid scale-up of HPV vaccination
por: Zou, Zhuoru, et al.
Publicado: (2023)

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study
por: De Vincenzo, Rosa, et al.
Publicado: (2021)

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial
por: Garland, Suzanne M., et al.
Publicado: (2016)

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial
por: Leung, Ting Fan, et al.
Publicado: (2015)

Immune Response to Human Papillomavirus One Year after Prophylactic Vaccination with AS04-Adjuvanted HPV-16/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sspll6a7ce26drju5dhcji8e69